PDF(Pubmed)
Abstract：
We enrolled 21 patients with laboratory-confirmed yellow fever (YF), hospitalized at Eduardo de Menezes Hospital, Brazil, to be treated with sofosbuvir, a drug approved for hepatitis C. Given the absence of specific YF antiviral treatments, the off-label nonrandomized sofosbuvir treatment aimed to address high disease severity and the risk of fatal outcomes. Patients received a daily dose of 400 mg sofosbuvir from 4 to 10 days post-symptom onset. YF viral load (VL) comparisons were made between treated and nontreated patients who either survived or died. The genomic VL for the treated group steadily decreased after day 7 post-symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir\'s role in YF treatment.
摘要：
我们招募了21例实验室确诊的黄热病（YF）患者，在EduardodeMenezes医院住院,巴西,用sofosbuvir治疗,一种批准用于丙型肝炎的药物，由于缺乏特定的YF抗病毒治疗，超标签非随机索非布韦治疗旨在解决高疾病严重程度和致命性结局风险.患者在症状发作后4至10天接受400mg索非布韦的日剂量。在存活或死亡的治疗和未治疗患者之间进行YF病毒载量（VL）比较。治疗组的基因组VL在症状发作后第7天稳定下降，表明索非布韦可能会降低YFVL。这项研究强调了对YF抗病毒治疗的迫切需要，倡导随机临床试验，以进一步探索索非布韦在YF治疗中的作用。
